AAP
PSTX

Arax Advisory Partners’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Arax Advisory Partners’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-38
Closed -$109 – 2804
2024
Q3 		$109 Hold
38
– – ﹤0.01% 2557
2024
Q2 		$111 Buy
+38
New +$104 ﹤0.01% 2487

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Arax Advisory Partners's PSTX Position: Q4 2024 in Review

Arax Advisory Partners sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 38 shares — an estimated $109 sold.

Arax Advisory Partners first reported a position in PSTX in Q2 2024 and held it in 2 quarters. The position peaked at $111 in Q2 2024. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • Arax Advisory Partners reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Arax Advisory Partners sold 38 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $109.
  • Arax Advisory Partners first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2024 and held it in 2 quarters.
  • Arax Advisory Partners's Poseida Therapeutics, Inc. Common Stock position peaked at $111 in Q2 2024.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.